Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Optimal management in mTNBC: What have we learned from clinical practice?

Date

12 May 2023

Session

Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Topics

Tumour Site

Breast Cancer

Presenters

Mafalda Oliveira

Authors

M. Oliveira

Author affiliations

Vall d'Hebron University Hospital, Barcelona/ES

Resources

This content is available to ESMO members and event participants.

Resources from the same session

12 May 2023

Welcome and introduction - Treatment landscape and emerging needs in metastatic breast cancer: Where are we today?

Presenter: Wolfgang Janni

Session: Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Resources:

Webcast

12 May 2023

A new era of treatment for HR+/HER2- mBC: What do the clinical data tell us?

Presenter: Komal Jhaveri

Session: Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Resources:

Webcast

12 May 2023

Closing remarks

Presenter: Wolfgang Janni

Session: Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Resources:

Webcast